|                                | 2000-2009 (n=51) | 2010-2018 (n=111) | p-value |
|--------------------------------|------------------|-------------------|---------|
| Age (yr)                       |                  |                   | 0.738   |
| ≥ 10                           | 17 (33.3)        | 40 (36.0)         |         |
| Sex                            |                  |                   | 0.995   |
| Male                           | 28 (54.9)        | 61 (55.0)         |         |
| Female                         | 23 (45.1)        | 50 (45.0)         |         |
| Performance status             |                  |                   | 0.574   |
| < 80                           | 26 (52.0)        | 63 (56.8)         |         |
| ≥ 80                           | 24 (48.0)        | 48 (43.2)         |         |
| MRI features                   |                  |                   |         |
| Extrapontine extension         | 36 (70.6)        | 88 (80.0)         | 0.187   |
| Enhancement                    | 35 (70.0)        | 68 (62.4)         | 0.351   |
| Infiltrative margin            | 28 (56.0)        | 66 (59.5)         | 0.680   |
| Cyst or necrosis               | 18 (35.3)        | 43 (38.7)         | 0.674   |
| Hydrocephalus                  | 6 (11.8)         | 17 (15.3)         | 0.548   |
| WHO grade                      |                  |                   | 0.259   |
| Grade 2                        | 0                | 4 (11.8)          |         |
| Grade 3                        | 5 (50.0)         | 9 (26.5)          |         |
| Grade 4                        | 5 (50.0)         | 21 (61.8)         |         |
| Surgery                        | 29 (21.6)        | 8 (29.6)          | 0.368   |
| RT modality                    |                  |                   | < 0.001 |
| 2D                             | 8 (15.7)         | 0                 |         |
| 3D-CRT                         | 34 (66.7)        | 29 (26.1)         |         |
| IMRT                           | 5 (9.8)          | 64 (57.7)         |         |
| Proton                         | 4 (7.8)          | 18 (16.2)         |         |
| CCRT                           | 25 (49.0)        | 53 (47.7)         | 0.880   |
| Adj. chemotherapy              | 20 (39.2)        | 38 (34.2)         | 0.539   |
| Salvage treatment              | 13 (27.1)        | 36 (42.4)         | 0.080   |
| Post-RT necrosis               |                  |                   | 0.622   |
| No or decreased                | 23 (50.0)        | 56 (54.4)         |         |
| Increased                      | 23 (50.0)        | 47 (45.6)         |         |
| Imaging response after RT      |                  |                   | 0.641   |
| CR                             | 2 (4.0)          | 2 (1.8)           |         |
| Treatment | Value 1 | Value 2 |
|-----------|---------|---------|
| PR        | 25 (50.0) | 47 (42.7) |
| SD        | 13 (26.0) | 36 (32.7) |
| PD        | 10 (20.0) | 25 (22.7) |

Values are presented as number (%). 2D, 2-dimensional; 3D-CRT, 3-dimensional conformal radiotherapy; Adj., adjuvant; CCRT, concurrent chemoradiotherapy; CR, complete response; IMRT, intensity-modulated radiotherapy; MRI, magnetic resonance image; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; WHO, World Health Organization.